TCRX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer...

Stats
Šios dienos apimtis	92 052.00
Vidutinė apimtis	196 857
Rinkos kapitalizacija	319.19M
EPS	$0 ( 2024-03-13 )
Kita pelno data	( $-0.250 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.42
ATR14	$0.0240 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Baker Bros. Advisors Lp	Buy	8 851 451	Warrants to purchase Common Stock
2024-04-19	Baker Bros. Advisors Lp	Buy	825 968	Warrants to purchase Common Stock
2024-04-19	Lynx1 Capital Management Lp	Buy	5 000 000	Pre-funded Warrant (right to buy)
2024-02-01	Amello Jason	Buy	750 000	Stock Option (Right to Buy)
2024-01-29	Amello Jason	Buy	0

INSIDER POWER
99.17
Last 93 transactions
Buy: 66 481 256 \| Sell: 5 443 695

Tūris Koreliacija

Ilgas: -0.10 (neutral)

Trumpas: -0.69 (moderate negative)

Signal:(43.678) Neutral

TScan Therapeutics, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
CRSA	0.871
HALL	0.871
MVBF	0.868
SNCR	0.859
OSMT	0.857
MYNA	0.84
SOUN	0.839
KFRC	0.824
LMFA	0.823
LMNL	0.819

10 Labiausiai neigiamai susiję koreliacijos
SLVO	-0.879
BNIXU	-0.864
BMRN	-0.85
ARTNA	-0.848
MRNA	-0.839
FNKO	-0.838
CAMP	-0.836
FNWD	-0.823
AVDX	-0.815

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

TScan Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos

0.20
( neutral )

-0.35
( neutral )

0.00
( neutral )

0.17
( neutral )

-0.10
( neutral )

0.36
( neutral )

TScan Therapeutics, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$21.05M
Bruto pelnas:	$15.69M (74.53 %)
EPS:	$-1.360

FY	2023
Pajamos:	$21.05M
Bruto pelnas:	$15.69M (74.53 %)
EPS:	$-1.360

FY	2022
Pajamos:	$13.54M
Bruto pelnas:	$8.40M (62.05 %)
EPS:	$-2.74

FY	2021
Pajamos:	$10.14M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-4.17

Financial Reports:

No articles found.

TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.